Avitar to Participate in ASSE Technical Meeting on Workplace Substance Abuse Testing
10 February 2006 - 12:30AM
PR Newswire (US)
CANTON, Mass., Feb. 9 /PRNewswire-FirstCall/ -- Avitar, Inc.
(OTC:AVRN) (BULLETIN BOARD: AVRN) , developer of the world's first
on-site, oral fluid-based test for drugs-of-abuse, will present at
the "Workplace Substance Abuse Testing" technical meeting organized
by the Greater Boston Chapter of the American Society of Safety
Engineers (ASSE). Steve Turko, National Accounts Director for
Construction of Avitar was invited to speak at the event beginning
at 5:30 pm on February 15, 2006 at Desmond O'Malley's Irish Pub
& Restaurant in Framingham, MA. During his presentation, Turko
will discuss the advantages of oral fluid- based on-site drug
testing, one of the most cost-effective and reliable methods to
reduce employee drug abuse. Additionally, Turko will highlight
strategies for implementing successful drug testing programs,
specifically: the advantages of random drug testing in reducing
accidents, creating a better work environment for all employees and
improving a corporation's bottom line. Other panelists at the
meeting will examine various alternative methods for substance
abuse testing, which will be followed by a question and answer
session for attendees. WHO: Steve Turko, National Accounts
Director, Construction, Avitar Inc. WHAT: "Workplace Substance
Abuse Testing 101" WHEN: Wednesday, February 15, 2006 from 5:30 to
8.30 p.m. WHERE: Desmond O'Malley's Irish Pub & Restaurant
Route 9 East Framingham, MA About Avitar Avitar, Inc. develops,
manufactures and markets innovative and proprietary products. Their
field includes the oral fluid diagnostic market, the disease and
clinical testing market, and customized polyurethane applications
used in the wound dressing industry. Avitar manufactures
ORALscreen(R), the world's first non-invasive, rapid, onsite oral
fluid test for drugs-of-abuse, as well as HYDRASORB(R), an
absorbent topical dressing for moderate to heavy exudating wounds.
Avitar is also developing diagnostic strategies for disease and
clinical testing in the estimated $25 billion in-vitro diagnostics
market. Conditions targeted include influenza, diabetes, and
pregnancy. For more information, see Avitar's website at
http://www.avitarinc.com/. Company Contact: PR Contact: Peter
Cholakis Maura Landry Avitar Inc. SHIFT Communications 781-821-2440
x117 617-681-1229 First Call Analyst: FCMN Contact: DATASOURCE:
Avitar, Inc. CONTACT: Peter Cholakis of Avitar Inc.,
+1-781-821-2440 ext. 117, ; or Maura Landry of SHIFT
Communications, +1-617-681-1229, Web site:
http://www.avitarinc.com/
Copyright